Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Usefulness of Microbiological Tests in Community-Acquired Pneumonia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2009 by Hospital Arnau de Vilanova.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hospital Arnau de Vilanova
ClinicalTrials.gov Identifier:
NCT00312741
First received: April 7, 2006
Last updated: February 26, 2009
Last verified: February 2009
  Purpose

The hypothesis is that community-acquired pneumonia is usually a monomicrobial infection. Therefore, early detection of the etiology allows to select the most active, narrow-spectrum, and cheap, and less toxic antibiotic agent.


Condition Intervention
Community-Acquired Pneumonia
Procedure: empirical versus microbiological guided treatment

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prospective Study on Benefits Derived From Microbiological Tests in Community-Acquired Pneumonia

Resource links provided by NLM:


Further study details as provided by Hospital Arnau de Vilanova:

Primary Outcome Measures:
  • Clinical and economic consequences obtained with the antibiotic selection in basis to early mcrobiological results

Secondary Outcome Measures:
  • Importance of polimicrobial etiology in community-acquired pneumonia
  • Practice usefulness of urinary antigen detection tests in pneumonia

Estimated Enrollment: 250
Study Start Date: April 2006
Estimated Study Completion Date: May 2008
Detailed Description:

In community-acquired pneumonia, identification of the etiologic agent has theoretically important advantages. For individual patients, it facilitates the administration of a targeted, narrow-spectrum antibiotic therapy that may improve the efficacy of treatment, and reduces risks of antibiotic-related toxicity. For the community, microbiologic results contribute to understanding the local microbial epidemiology of community-acquired pneumonia and the antimicrobial resistance patterns of pathogens, information that is essential in the instauration or modification of empiric treatment regimens.

Guidelines recommend that all admitted patients with community-acquired pneumonia should have a collection of two sets of blood cultures, a good quality sputum sample for Gram stain and culture, a sample of pleural fuid if present and, for severe patients, an urine sample for antigen detection. In contrast, several prospective studies (usually without include urinary tests) concluded that these microbiological studies have limited value in the management of patients admitted with community-acquired pneumonia.

In addition, microbiological studies could provide erroneous or incomplete information. Thus, investigations has showed false-positive results from pneumococcal antigen detection in urine caused by a frequent persistence of positivity after infection or a nasopharyngeal or bronchial colonization. Other authors suggested that community-acquired pneumonia is a polymicrobial infection; consequently, despite the detection of a true microorganism, treatment needs to be also addressed against other potential pathogenic agents.

The purpose of the study is to assess the clinical and the economic derived from the initial microbiological studies, including antigen detection tests in urine for Streptococcus pneumoniae and Legionella pneumophila, in patients with community-acquired pneumonia.

The hypothesis is that community-acquired pneumonia is usually a monomicrobial infection. Therefore, early detection of the etiology allows to select the most active, narrow-spectrum, and cheap, and less toxic antibiotic agent.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age: 18 years and above
  • Clinical and radiological diagnosis of community-acquired pneumonia
  • Informed consent of patient
  • Hospital admission

Exclusion Criteria:

  • Prior hospital admission (less than 15 days)
  • Alternative diagnosis at the discharge
  • Immunosuppression (HIV infection, immunosuppressive therapies, neutropenia)
  • Risk factors for unusual etiologies
  • Patient is pregnant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00312741

Contacts
Contact: Miquel Falguera, M.D. 0034-973248100 ext 2679 mfalguera@comll.cat

Locations
Spain
Hospital Arnau de Vilanova Recruiting
Lleida, Spain, 25198
Contact: Miquel Falguera, M.D.    0034-973248100 ext 2679    mfalguera@comll.es   
Sub-Investigator: Agustin Ruiz-González, M.D.         
Sponsors and Collaborators
Hospital Arnau de Vilanova
Investigators
Principal Investigator: Miquel Falguera, M.D. Hospital Arnau de Vilanova (Lleida)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00312741     History of Changes
Other Study ID Numbers: pneumonia1
Study First Received: April 7, 2006
Last Updated: February 26, 2009
Health Authority: Spain: Comité Ético de Investigación Clínica

Keywords provided by Hospital Arnau de Vilanova:
community-acquired pneumonia
microbiological tests
urinary antigen
selection of antibiotic treatment

Additional relevant MeSH terms:
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections

ClinicalTrials.gov processed this record on November 24, 2014